MRK · 10-Q · 2026Q3 · Full report

Animal Health Demand

Merck & Co., Inc. · 2026-11-04 · Importance 18 · Surprise 14 · In source text

Companion animal product sales grew 6% in the third quarter and 8% in the first nine months of 2026, driven largely by new product launches and partly offset by lower vaccine pricing. Bravecto sales were $264 million in the quarter, up 1% (flat excluding foreign exchange), and $1.0 billion year to date, up 8% (5% excluding foreign exchange). Merck said lower demand for other portfolio products partially offset year-to-date growth. Numelvi, approved in February 2026, is the first and only second-generation JAK inhibitor indicated to control pruritus associated with allergic dermatitis in dogs six months and older.

Key facts

• The FDA approved Numelvi (atinvicitinib tablets) in February 2026 as the first and only second-generation JAK inhibitor indicated to control pruritus associated with allergic dermatitis in dogs six months of age and older. source
• Bravecto line sales were $1.0 billion in the first nine months of 2026, up 8% or 5% excluding foreign exchange, versus the same period of 2025. source
• Bravecto line sales were $264 million in Q3 2026, up 1% or flat excluding foreign exchange, versus Q3 2025. source
• Livestock product sales grew 2% in Q3 2026, primarily due to higher poultry demand, and 8% in the first nine months, primarily due to higher ruminant and poultry demand. source
• Companion animal product sales grew 6% in Q3 2026 and 8% in the first nine months of 2026, largely driven by new product launches and partially offset by lower pricing, primarily for vaccines. source
• Animal Health sales growth was due to livestock and companion animal products. source

Impact estimates